On 4/6/2017, Shares of Robert Half International Inc. (NYSE:RHI) closed at $45.73 in last trading day. After noting the initial trading entry at $45.69, it reached to a day’s high of $46.06 and moved to a day’s low of $45.13. The recent daily volume was 987.96 thousand as contrast to it’s an average volume of 1.2 million.
The last close of the Robert Half International Inc. stock reflects that it traded -4.71% from its 50-day moving average of $47.99. The stock traded above +1.63% to its 200-day MA of $45.00. Furthermore, it moved lower -10.30% from its 52-week high of $50.98 and +33.17% up from $34.34, which is 52-week low of the stock.
Robert Half International Inc.’s (RHI) moved with shift of -5.94% in the past week. Over the last three months, the shares of the company have changed -5.44% and performed 21.99% over the last six months. The stock currently has Monthly Volatility of 1.89% and Weekly Volatility of 2.70%.
Robert Half International Inc. provides staffing and risk consulting services in North America, South America, Europe, Asia, and Australia. The company operates through three segments: Temporary and Consultant Staffing, Permanent Placement Staffing, and Risk Consulting and Internal Audit Services. It places temporary personnel for accounting, finance, and bookkeeping; temporary and full-time office and administrative personnel consisting of executive and administrative assistants, receptionists, and customer service representatives; full-time accounting, financial, tax, and accounting operations personnel; and information technology contract consultants and full-time employees in the areas of platform systems integration and end-user support, including specialists in Web development, networking, application development, systems integration, database design, security and business continuity, and desktop support. The company also offers temporary and full-time employees in attorney, paralegal, legal administrative, and legal secretarial positions; senior level project professionals in the accounting and finance fields for financial systems conversions, expansion into new markets, business process reengineering, business systems performance enhancement, and post-merger financial consolidation. In addition, it is involved in serving professionals in the areas of interactive media, design, marketing, advertising, and public relations; and placing project consultants in various positions, such as creative directors, graphics designers, Web content developers, Web designers, media buyers, brand managers, and public relations specialists. Further, the company provides business and technology risk consulting, and internal audit services. It markets its staffing services to clients, as well as to employment candidates. The company was founded in 1948 and is headquartered in Menlo Park, California.
Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) finalized the last transaction at value of $0.64, with a daily change of +0.79% or +0.00 points. The company maintained volume of 937.29 thousand shares. In past trading day, the stock hit the maximum price of $0.65 and touched to minimum value of $0.62. It has a market cap of $ 190.53M.
As of last trade close, the stock is trading downside -17.31% from its one year high of $0.77 and moved +126.95% upward from $0.28, which is one year low of the stock.
The stock traded below -0.71% from its 50-day moving average of $0.64. Furthermore, the stock moved up +54.87% to its 200-day MA of $ 0.41.
During the last month, Peregrine Pharmaceuticals, Inc.’s (PPHM) has changed -5.88% and performed 45.45% over the last 6 months. The mean rating score for this stock is at 1.50. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 7.68% in recent month and observed Weekly Volatility of 4.63%.
Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops monoclonal antibodies for the treatment of cancer in the United States. It’s lead immunotherapy candidate bavituximab, a monoclonal antibody that targets and binds to phosphatidylserine. The company also provides integrated current good manufacturing practices services from cell line development to commercial bio manufacturing for its third-party customers. In addition, its services comprise cGMP clinical and commercial manufacturing utilizing stainless steel and single use bioreactor technology, purification, bulk packaging, stability testing, regulatory strategy and related support. The company has license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; Merck KGaA; and National Comprehensive Cancer Network, as well as collaboration agreement with AstraZeneca PLC and Memorial Sloan Kettering Cancer Center. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.